Across TCGA pan-cancer cohorts, CSF2RA mass-spec protein is linked to patient survival in 2 of 34 cancer types, making it a survival-associated CSF2RA data layer compared with 24 for mass-spec protein and 7 for mutation status.
The strongest signal is observed in lung adenocarcinoma (LUAD), where higher CSF2RA mass-spec protein is associated with worse overall survival. In most high-consensus cancer types, elevated CSF2RA expression acts as an unfavorable survival marker.
LUAD and LSCC are the cancer types where CSF2RA mass-spec protein most reproducibly stratifies survival.